Key result
Proposed strategies for managing clopidogrel hypersensitivity include treatment with an alternative P2Y12 inhibitor, cilostazol, or warfarin.
Why the study?
Hypersensitivity reactions to clopidogrel can cause therapy discontinuation and increase vascular event risks, prompting the need for alternative antiplatelet strategies.
What are the recommended alternative antiplatelet agents for patients with clopidogrel hypersensitivity?
What are the recommended alternative antiplatelet agents for patients with clopidogrel hypersensitivity?
For patients with clopidogrel hypersensitivity, alternative P2Y12 inhibitors, cilostazol, or warfarin are recommended to maintain secondary prevention of vascular events.
Answers are grounded in this paper and cite their sources.
Clopidogrel alternatives may warrant consideration in hypersensitivity; leaves open need for RCTs before guiding practice.
Clopidogrel is a widely used agent for secondary prevention of vascular events and is a cornerstone of dual antiplatelet therapy in patients with acute coronary syndrome (ACS) post coronary stent implantation. Hypersensitivity reactions to clopidogrel are well documented and may range from localized to systemic in presentation. This can lead to discontinuation of therapy, thus increasing the risk of vascular events. The authors have developed recommendations for potential alternative agents for the management of clopidogrel hypersensitivity reactions. Proposed strategies include treatment with an alternative P2Y12 inhibitor, cilostazol or warfarin.
No takes yet. Share an insight, caveat, or question.
Ather et al. (2019) conducted a review in Clopidogrel hypersensitivity. Alternative antiplatelet agents (alternative P2Y12 inhibitor, cilostazol, or warfarin) was evaluated. Proposed strategies for managing clopidogrel hypersensitivity include treatment with an alternative P2Y12 inhibitor, cilostazol, or warfarin.
Synapse has enriched 10 related papers. Consider them for comparative context: